Tirzepatide
Also referred to as: LY3298176, GIP/GLP-1 dual agonist
A peptide built to act on two metabolic targets at once (GIP and GLP-1). Widely studied in connection with blood sugar and weight and fat loss.
In plain terms: Tirzepatide is a peptide designed to act on two of the body's metabolic "switches" at the same time. It has been studied heavily in people for blood sugar control and weight and fat loss, and it is approved as a medicine in some places for specific uses. As a research compound it is among the most-tested on this site.
- Name
- Tirzepatide
- Aliases
- LY3298176, GIP/GLP-1 dual agonist
- Classification
- Dual receptor agonist (peptide)
- Areas studied
- GIP/GLP-1, Blood-sugar signals, Metabolic research
What it is
Tirzepatide is a lab-made peptide built to act on two metabolic targets at once — the GIP and GLP-1 receptors. (Receptors are the docking points on cells that hormones plug into to send a signal.) It is one of the best-known examples of a "dual-target" peptide.
It has a large record of registered clinical trials in people and comes up constantly in metabolism research.
Mechanism
Tirzepatide plugs into both the GIP and GLP-1 receptors, two of the body's signals that help control blood sugar and appetite. Acting on both at once with a single molecule is the central idea behind its design.
Research looks at how hitting both of these pathways together affects the body's metabolism, including blood sugar and weight and fat loss.
Areas studied & investigated
The categories below summarize where Tirzepatide appears in the research literature. They describe what the compound is studied for and investigated in — not approved uses, and not guidance for any kind of use.
GIP signal
Studied for how it acts on the GIP pathway, one of the body's blood-sugar and appetite signals.
GLP-1 signal
Acts on the GLP-1 pathway, a long-studied signal in blood-sugar control.
Weight & fat loss
Studied in clinical trials in connection with body weight and fat loss.
Dual-target design
A leading research example of one molecule built to act on two targets at once.
Research history
Tirzepatide came out of research into dual-target metabolic peptides and moved through registered clinical trials in the late 2010s and early 2020s, with results published in major medical journals.
State of the literature
Tirzepatide has a large body of peer-reviewed human research and is approved in some places for specific uses. Research and reference interest remain high. Use outside those approved uses is not established.
What to keep in mind
Tirzepatide is unusual here: it has been approved as a real medicine in some places, with extensive human trials behind it. But "approved for a specific medical use under a doctor" is a completely different thing from a research-use-only compound bought online. The safety data comes from supervised medical use at studied doses — none of which applies to unsupervised use of a research product. Keep those two worlds firmly separate.
Research tools
Evaluating a Tirzepatide batch for laboratory research? These free, research-use-only calculators help you work the numbers and read the paperwork: the reconstitution calculator solves vial concentration and draw volume, and the COA reader walks a certificate line by line. For how much and how often Tirzepatide is commonly used, see the dosing guides.
Batch-tested with published COAs
See a published COA for Tirzepatide
Midwest Compounds sells Tirzepatide with a batch-linked certificate of analysis from an independent lab, published before you buy. This page is educational; purchasing happens on the store.
Citations
The summary above is drawn from published, peer-reviewed sources. Links open the abstract on PubMed, or the free full text on PubMed Central (PMC) where marked.
- Frías JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 2021. Abstract
- Coskun T, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. Molecular Metabolism, 2018. Abstract